Table 1 |
||
|
Demographic, clinical, and therapy variables |
||
| Variables |
All patients (n = 103) |
Healthy controls |
|
|
||
| Demographic variables |
||
| Female gender, percentage |
91 |
|
| Caucasian race, percentage |
77 |
|
| Age, years |
41 ± 13 |
|
| Comorbidity |
||
| Diabetes mellitus, percentage |
4.9 |
|
| Clinical and laboratory variables |
||
| Disease duration, years |
6.8 ± 4 |
|
| SLEDAI |
4.7 ± 4 |
|
| ECLAM |
3.1 ± 1.6 |
|
| SLICC/ACR damage index |
1.4 ± 1.9 |
|
| Previous biopsy proven lupus nephritis, percentage |
31.1 |
|
| Creatinine clearance <70 ml/minute, percentage |
18 |
|
| Proteinuria, percentage |
13.6 |
|
| Leucopoenia ever, percentage |
36.9 |
|
| Functional MBL serum level, median (range) μg/ml |
1.4 (0.04–7.60) |
1.1 (0.0–11.2) |
| Functional MBL serum level <0.05 μg/ml, percentage |
13 |
14 |
| MBL-induced C4 deposition on mannan, median (range) percentage |
71 (1.1–399) |
114 (3–494) |
| MBL-induced C4 deposition on mannan <10%, percentage |
21 |
16 |
| Functional activity of the MBL pathway, median (range) percentage |
16 (0.1–119) |
56 (0–133) |
| Functional activity of the MBL pathway <10%, percentage |
43 |
28 |
| C3 levels in serum, median (range) g/l |
0.86 (0.06–1.70) |
(0.88–2.01) |
| C4 levels in serum, median (range) g/l |
0.13 (0.07–0.35) |
0.21 (0.11–0.61) |
| Therapy variables |
||
| Oral corticosteroids |
||
| Ever user, percentage |
81 |
|
| Current user, percentage |
52 |
|
| Duration of corticosteroid use in ever users, months |
63 ± 70 |
|
| Actual prednisone dose if >0 mg/day, mg |
13 ± 12 |
|
| Intravenous methylprednisolone use ever, percentage |
15 |
|
| Hydroxychloroquine use ever, percentage |
87 |
|
| Azathioprine use ever, percentage |
37 |
|
| Methotrexate use ever, percentage |
14 |
|
| Cyclophosphamide (oral and/or intravenous) use ever, percentage |
13 |
|
|
|
||
|
Except where indicated otherwise, values are presented as the mean ± standard deviation. ECLAM, European consensus lupus activity measurement (range 0 to 10) [35]; MBL, mannose-binding lectin; SLEDAI, systemic lupus erythematosus disease activity index (range 0 to 105) [36]; SLICC/ACR, Systemic Lupus International Collaborating Clinics/American College of Rheumatology [37]. |
||
|
Bultink et al. Arthritis Research & Therapy 2006 8:R183 doi:10.1186/ar2095 |
||
